Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20077090 | 0.95 | NR1H2 (0.42) | NR1H2NR1H3SCN9AGPR119CHRM4 | |
| SCHEMBL20077736 | 0.95 | NR1H2 (0.42) | NR1H2NR1H3SCN9AGPR119CHRM4 | |
| SCHEMBL22894976 | 0.93 | NR1H2 (0.41) | NR1H2NR1H3SCN9AGPR119 | |
| SCHEMBL22894954 | 0.93 | NR1H2 (0.41) | NR1H2NR1H3SCN9AGPR119CCR3 | |
| SCHEMBL20077091 | 0.93 | NR1H2 (0.41) | NR1H2NR1H3SCN9AGPR119 | |
| SCHEMBL20077708 | 0.93 | NR1H2 (0.41) | NR1H2NR1H3SCN9AGPR119CCR3 | |
| SCHEMBL22894988 | 0.92 | NR1H2 (0.44) | NR1H2NR1H3SCN9AGPR119 | |
| SCHEMBL20077328 | 0.92 | NR1H2 (0.44) | NR1H2NR1H3SCN9AGPR119 | |
| SCHEMBL20077707 | 0.92 | CCR3 (0.38) | NR1H2NR1H3SCN9AGPR119CCR3 | |
| SCHEMBL22894975 | 0.91 | NR1H2 (0.43) | NR1H2NR1H3SCN9AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-01-19 | — | — | US | disclosed |
| WO-2018071315-A2 | PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018068296-A1 | PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894775-B2 | Piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, ADRB1 | NR1H2 1/4885NR1H3 2/4885SCN9A 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.